NZ242724A - Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker - Google Patents

Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker

Info

Publication number
NZ242724A
NZ242724A NZ242724A NZ24272492A NZ242724A NZ 242724 A NZ242724 A NZ 242724A NZ 242724 A NZ242724 A NZ 242724A NZ 24272492 A NZ24272492 A NZ 24272492A NZ 242724 A NZ242724 A NZ 242724A
Authority
NZ
New Zealand
Prior art keywords
angiotensin
receptor antagonist
calcium channel
channel blocker
synergistic composition
Prior art date
Application number
NZ242724A
Other languages
English (en)
Inventor
Pancras Chor Bun Wong
Original Assignee
Du Pont
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont filed Critical Du Pont
Publication of NZ242724A publication Critical patent/NZ242724A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ242724A 1991-05-15 1992-05-13 Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker NZ242724A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15

Publications (1)

Publication Number Publication Date
NZ242724A true NZ242724A (en) 1994-09-27

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ242724A NZ242724A (en) 1991-05-15 1992-05-13 Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker

Country Status (11)

Country Link
EP (1) EP0584250A1 (ja)
JP (1) JP2930252B2 (ja)
AU (1) AU664375B2 (ja)
CA (1) CA2103276A1 (ja)
CZ (1) CZ281570B6 (ja)
IE (1) IE921534A1 (ja)
IL (1) IL101858A (ja)
MX (1) MX9202243A (ja)
NZ (1) NZ242724A (ja)
WO (1) WO1992020342A1 (ja)
ZA (1) ZA923557B (ja)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
AU696868B2 (en) * 1994-03-29 1998-09-17 Merck & Co., Inc. Treatment of atherosclerosis with angiotensin II receptor blocking imidazoles
PT804229E (pt) 1995-03-16 2003-06-30 Pfizer Utilizacao de amlodipina de um dos seus sais ou defelodipina em combinacao com um inibidor da en zima de conversao da angiotensina (ace) para no fabrico de um medicamento destinado ao tratamento da insuficiencia cardiaca congestiva nao isquemica
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
ID27664A (id) 1998-07-10 2001-04-19 Novartis Ag Kombinasi antihipersensitif dari valsartan dan penghalang saluran kalsium
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
TWI290470B (en) * 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
WO2001082858A2 (de) * 2000-05-04 2001-11-08 Ipf Pharmaceuticals Gmbh Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
EP3045174A1 (en) * 2003-01-31 2016-07-20 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (fr) * 1986-11-20 1990-06-01 Synthelabo Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2020073A1 (en) * 1989-07-03 1991-01-04 Eric E. Allen Substituted quinazolinones as angiotensin ii antagonists
KR100222252B1 (ko) * 1990-12-14 1999-10-01 스튜어트 알. 수터 안지오텐신 ii 수용체 차단 조성물

Also Published As

Publication number Publication date
AU664375B2 (en) 1995-11-16
WO1992020342A1 (en) 1992-11-26
EP0584250A1 (en) 1994-03-02
IE921534A1 (en) 1992-11-18
EP0584250A4 (ja) 1994-03-30
JP2930252B2 (ja) 1999-08-03
AU2026992A (en) 1992-12-30
CA2103276A1 (en) 1992-11-16
IL101858A0 (en) 1992-12-30
JPH06508128A (ja) 1994-09-14
ZA923557B (en) 1993-11-15
CZ281570B6 (cs) 1996-11-13
IL101858A (en) 1996-08-04
CZ235193A3 (en) 1994-03-16
MX9202243A (es) 1992-11-01

Similar Documents

Publication Publication Date Title
NZ242724A (en) Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
ZA92990B (en) Calcium channel antagonists and methodology for their identification
GB2284820B (en) Flushable compositions
HUP9901779A3 (en) Modified release multiple-units dosage composition
HU9700410D0 (en) Cosmetic composition containing a neuropeptide y receptor antagonist
ZA93550B (en) Azabricyclic compounds as calcium channel antagonists
HU9503067D0 (en) Endotheline receptor antagonists
IL101281A0 (en) Anti-cancer compounds and compositions
HUT61206A (en) Air-freshing composition
HU207113B (en) Bitumen composition
EP0510591A3 (en) Polymer compositions and their blends
IL102372A0 (en) Pharmaceutical composition containing a non-n-methyl-d-aspartate antagonist
GB9324606D0 (en) Angiotensin-ii receptor blocking cycloakylbenzylimidazoles
HUP9903619A3 (en) Pharmaceutical composition containing a 5ht2c antagonist and a d2 antagonist
IL90189A0 (en) Pharmaceutical compositions containing a benzazepine-type calcium channel blocker
GB2274650B (en) Composition for skin barrier
PL289906A1 (en) Fireproofing composition
GB9204019D0 (en) Bis-bibenzimidazole composition
GB9122979D0 (en) Groung anchorage
GB9113453D0 (en) Anchorage
GB9108857D0 (en) Spreading device
EP0520675A3 (en) Flushable delay line
IL102562A0 (en) Antibody composition acting synergistically
GB2276100B (en) Bituminous composition
BG94782U (en) Composition for fire-extinguishing

Legal Events

Date Code Title Description
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)
EXPY Patent expired